The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

Introduction Malaria, a devastating febrile illness caused by protozoan parasites, sickened
247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in …

Plasmodium vivax infection, the predominant cause of malaria in Asia and Latin America,
affects~ 14 million individuals annually, with considerable adverse effects on wellbeing and …

Malaria is one of the most devastating human infectious diseases caused by Plasmodium
spp. parasites. A search for an effective and safe vaccine is the main challenge for its …

Plasmodium vivax is the most widespread human malaria parasite, in part because it can
form latent liver stages known as hypnozoites after transmission by female anopheline …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Plasmodium falciparum and Plasmodium vivax cause the majority of human malaria cases.
Research efforts predominantly focus on P. falciparum because of the clinical severity of …